Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 4/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3227245 | 0.88 | CXCR2 (0.78) | CXCR2KMT2AMEN1MAPTLMNA | |
| SCHEMBL3228209 | 0.85 | CXCR2 (1.00) | CXCR2KMT2AMEN1ATMNPC1 | |
| SCHEMBL3228417 | 0.85 | CXCR2 (0.74) | CXCR2KMT2AMEN1MAPTKDM4E | |
| SCHEMBL3218345 | 0.85 | CXCR2 (0.74) | CXCR2KMT2AMEN1MAPTLMNA | |
| SCHEMBL3217766 | 0.84 | CXCR2 (0.73) | CXCR2KMT2AMEN1MAPTKDM4E | |
| SCHEMBL3223328 | 0.83 | CXCR2 (0.59) | CXCR2TP53KMT2AMEN1MAPT | |
| SCHEMBL3225218 | 0.83 | MAPT (0.71) | CXCR2KMT2AMEN1MAPTKDM4E | |
| SCHEMBL3230684 | 0.82 | CXCR2 (0.70) | CXCR2TP53KMT2AMEN1MAPT | |
| SCHEMBL3227229 | 0.81 | CXCR2 (0.68) | CXCR2KMT2AMEN1MAPTKDM4E | |
| SCHEMBL3225459 | 0.81 | CXCR2 (0.68) | CXCR2KMT2AMEN1MAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063105-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | UCB SA (GB) | 2010-03-11 | — | — | US | disclosed |
| US-7141590-B2 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | UCB SA (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20050026965-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | DARWIN DISCOVERY LIMITED (GB) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063105-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | NNT, NAPRT, NNMT | CXCR2 1447/4885TP53 4461/4885KMT2A 2723/4885 |
| US-20050026965-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | NNT, NAPRT, NNMT | CXCR2 1447/4885TP53 4461/4885KMT2A 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.